Weekly Industry News: Pharma & Healthcare

Pharma & Healthcare – the latest on Pfizer Inc v. Teva Pharmaceuticals, the USFDA imposes penalties on Indian pharma cos’ and more.  

FDA panel could give Bayer painkiller an edge over rivals from Pfizer, J&J by Tracy Staton Published on  FiercePharma.com

What if every drug in a class posed a risk to the heart–all except one? That’s the question we could soon be asking about nonsteroidal anti-inflammatories, or NSAIDs, among the most commonly used drugs in the world… [ Read More ]

‘USFDA has imposed disproportionate penalties on Indian pharma cos’ by Amiti Sen Published on The Hindu Business Line

Reacting strongly to the recent string of actions against Indian pharmaceutical companies by the US Food & Drug Administration (FDA), India has said that in some cases the authority has imposed disproportionately strong penalties…[ Read More ]

Pfizer Inc. v. Teva Pharmaceuticals USA, Inc. (Fed. Cir. 2014) by Andrew Williams Published on jdsupra.com

The standard of review at the Federal Circuit is important.  Even though it often appears like cases are re-litigated at the Appeals Court, it is actually very difficult (or at least should be) to overturn a lower court’s factual determinations…[ Read More

Live Industry News

Twitter  Follow @ACI_Pharma & @ACI_Health   LinkedIn-Logo-2C (1)  Join ACI Pharmaceuticals/Biotech/Life Sciences Experts Group Join ACI Healthcare: Legal, Regulatory, and Compliance Experts Group

Related Events

Pharma BioTech Pharmaceutical Compliance & Enforcement 1 For the complete list of all Phamaceuticals  upcoming events: Click Here For the complete list of all Healthcare upcoming events: Click Here To download past Pharmaceuticals conference materials: Click Here To download past Healthcare conference materials: Click Here